Document is current
Any future updates will be listed below
-
Authors
Smith-Apeldoorn, Sanne Y.
Veraart, Jolien K. E.
Kamphuis, Jeanine
Spijker, Jan
van der Meij, Annemarie
van Asselt, Antoinette D. I.
aan het Rot, Marije
Schoevers, Robert A. https://orcid.org/0000-0003-0760-9866
-
Funding
Funding for this research was provided by:
ZonMw (80-83600-98-3074)
- License Information
-
More Information
Article History
Received: 20 September 2023
Revised: 23 January 2024
Accepted: 5 February 2024
First Online: 25 March 2024
Competing interests
: JV has received a speakers fee from Janssen Pharmaceuticals, outside the submitted work. RS has received research funding for two randomized clinical trials with generic oral esketamine from the Netherlands Organisation for Health Research & Development and the National Health Care Institute, a speakers fee and an investigator initiated research grant from Janssen Pharmaceuticals, and consultancy fees from Clexio biosciences, GH Research, Beckley PsyTech, and QPS. All other authors declare no competing interests.
